Stephens Initiates Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX)

Stephens started coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research note issued to investors on Monday, MarketBeat.com reports. The firm issued an overweight rating and a $35.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Citigroup increased their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:CPRX opened at $21.12 on Monday. Catalyst Pharmaceuticals has a 52 week low of $13.00 and a 52 week high of $24.27. The company’s 50 day moving average is $21.09 and its two-hundred day moving average is $18.47. The company has a market cap of $2.52 billion, a PE ratio of 17.90, a P/E/G ratio of 3.29 and a beta of 0.75.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CPRX. Sei Investments Co. raised its holdings in Catalyst Pharmaceuticals by 64.3% in the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock valued at $1,329,000 after acquiring an additional 32,621 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at $258,000. Integral Health Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at $4,260,000. GSA Capital Partners LLP acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at $625,000. Finally, Vanguard Group Inc. raised its holdings in Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.